Is Saxenda the Same as Mounjaro? What the Differences Actually Mean for You

Why the two medicines feel interchangeable, and why they are not

Both Saxenda and Mounjaro belong to a family of injectable weight-loss treatments sometimes lumped together in casual conversation. That grouping is understandable: both are given by subcutaneous injection, both slow gastric emptying to reduce hunger, and both are licensed in the UK for adults with a BMI of 30 or above, or 27 or above with at least one weight-related health condition. The surface similarities end there.

Saxenda's active ingredient is liraglutide, which activates a single receptor, the GLP-1 receptor. Mounjaro's active ingredient is tirzepatide, which activates two receptors simultaneously: GLP-1 and GIP. That dual action is why tirzepatide sits in its own pharmacological class and why the tirzepatide overview on this site covers it as a genuinely distinct treatment rather than an incremental update. The extra receptor pathway appears to drive a larger and more consistent reduction in body weight, based on the trial evidence available.

Injection frequency is also different in practice. Saxenda requires a daily injection, working up through a titration schedule. Mounjaro is once weekly, starting at 2.5 mg and titrated by the prescriber in four-week steps through six available strengths. For many people that frequency difference matters, a daily routine is easier to forget, harder to build around travel, and can feel more intrusive over time, and our guide to what Mounjaro is and how it compares covers those practical distinctions in more detail. Worth factoring in before you decide.

What the clinical evidence shows about results

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity over 72 weeks. Participants on the 15 mg tirzepatide dose lost an average of around 20–21% of body weight alongside lifestyle changes. That is a meaningful figure, and it should be understood as an average from a large clinical study, individual results differ.

Saxenda's pivotal trials produced average weight loss in the region of 5–7% over 56 weeks. Some participants lost considerably more; others less. The honest comparison is that Mounjaro's trial results are substantially larger on average, which is reflected in the NICE technology appraisal for tirzepatide (TA1026) and in the head-to-head data from SURMOUNT-5, where tirzepatide produced greater average weight reduction than semaglutide 2.4 mg, a medicine that itself outperforms liraglutide in the available evidence. For a fuller look at that comparison, the Saxenda versus Mounjaro page breaks the trial data down in more detail.

Side effects follow a similar pattern across both medicines: nausea, vomiting, constipation, and other gastrointestinal effects are the most common, typically most noticeable when starting treatment or moving to a higher dose before settling down. The NHS medicines information for tirzepatide notes the same GI-led profile documented in its clinical programme.

Where Saxenda stands in the UK today, and what is licensed now

This matters for a practical reason. Saxenda is licensed in the UK for weight management, but nume does not dispense Saxenda. The two medicines licensed and clinically reviewed through our GPhC-registered pharmacy are Mounjaro (tirzepatide) and Wegovy (semaglutide). Both are MHRA-licensed for weight management in adults who meet the eligibility criteria. Semaglutide (available as a weekly injection under the Wegovy brand) is a GLP-1 receptor agonist like liraglutide, but its trial results are substantially stronger than Saxenda's and it is available in a dedicated weight-loss treatment pathway. If you have been researching Saxenda, either of these is worth understanding as an alternative.

Mounjaro's NICE recommendation (TA1026, updated September 2025) covers adults with a BMI of 35 or above plus at least one weight-related comorbidity through the NHS route, with lower thresholds applying for some ethnic backgrounds under UK guidance. Private prescribing through a regulated pharmacy follows the licensed eligibility criteria in the SmPC (BMI 30 or above, or 27 or above with a qualifying condition) and always requires a prescriber to review the full clinical picture. BMI alone does not guarantee approval. For context on what private treatment typically costs, the Mounjaro cost guide covers what headline prices usually do and do not include.

The practical question: which medicine should you consider?

If you have been on Saxenda before, or been quoted it as an option, the question now is whether a more effective licensed alternative suits your situation. That is precisely the kind of decision our prescribers work through during a consultation. You will not be asked to self-diagnose or compare drug mechanisms on your own. A clinician on our team reads every submission the same day and assesses your history, current health, and goals before any prescription is written.

A quick check worth doing before you consult anyone: look up any online pharmacy you are considering on the GPhC pharmacy register. A registration number and a live GPhC entry take under a minute to verify and tell you whether the pharmacy is operating legally. It is the single most reliable indicator that a service is dispensing genuine, licensed medicines through regulated clinical oversight.

If you want to understand what tirzepatide actually is at a pharmacological level before deciding anything, the tirzepatide and Mounjaro explainer is a good starting point. When you are ready to talk to a prescriber, you can check your eligibility through a free consultation, reviewed the same working day.